8-K filing — Standard Nuclear, Inc. (STDN)
Filed: 2026-09-08 AccNo: 0001628280-26-060827 Size: 169 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Standard Nuclear Q2 EPS $(0.12) Misses $(0.02) Estimate, Sales $4.736M Beat $4.298M Estimate
Standard Nuclear (NYSE:STDN) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.02) by 500 percent. This is a 100 percent decrease over losses of $(0.06) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Standard Nuclear shares are trading higher after UBS maintained its Buy rating on the stock and raised its price target from $14 to $20.
UBS Maintains Buy on Standard Nuclear, Raises Price Target to $20
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)